Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Issue 2 (1st February 2022)
- Record Type:
- Journal Article
- Title:
- Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Issue 2 (1st February 2022)
- Main Title:
- Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma
- Authors:
- Elbaz, Tamer
Waked, Imam
El-Akel, Wafaa
Shaker, Mohamed Kamal
Abdelaziz, Ashraf Omar
Yousif, Monkez
El-Bendary, Mahmoud
Zaky, Samy
AbdAllah, Mohamed
Hassany, Mohamed
Esmat, Gamal
Doss, Wahid - Abstract:
- ABSTRACT: Background: There are many contradictory studies that dealt with hepatocellular carcinoma (HCC) recurrence rate of well ablated hepatitis C virus (HCV) related HCC. We aim to assess the recurrence rate of previously ablated HCC in patients who received direct acting antiviral (DAA) for their HCV. Research design and methods: This is a retrospective data analysis of 523 HCV patients who have a history of successfully ablated HCC and eligible for HCV treatment. Retrieval was done to demographic/clinical data, HCV pretreatment investigations, HCV treatment outcome. Follow up for survival and HCC recurrence was done every 3 months using abdominal ultrasound and alfa-fetoprotein. Results: Mean age was 53.83 years. Sofosbuvir/daclatasvir/ribavirin was the most used regimen (35.4%) with 438 patients (83.7%) achieved sustained virologic response (SVR). The median duration for surveillance was 159 weeks. Hundred and five patients developed recurrent HCC, with a crude recurrence rate of 20.1%. There was no difference between HCV responders and non-responders in crude recurrence rate (p = 0.94) but HCC developed earlier in non-responders (p = <0.01). Conclusion: Recurrence of HCC remains a threat in HCV patients even after achieving an SVR. Implementation of long-term surveillance programs is highly recommended.
- Is Part Of:
- Expert review of anti-infective therapy. Volume 20:Issue 2(2022)
- Journal:
- Expert review of anti-infective therapy
- Issue:
- Volume 20:Issue 2(2022)
- Issue Display:
- Volume 20, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 20
- Issue:
- 2
- Issue Sort Value:
- 2022-0020-0002-0000
- Page Start:
- 307
- Page End:
- 314
- Publication Date:
- 2022-02-01
- Subjects:
- HCV -- daas -- HCC -- recurrence -- SVR
Anti-infective agents -- Research -- Periodicals
616.90461 - Journal URLs:
- http://informahealthcare.com ↗
http://www.future-drugs.com/publication.asp?publicationid=7 ↗
http://www.tandfonline.com/toc/ierz20/current ↗ - DOI:
- 10.1080/14787210.2021.1951230 ↗
- Languages:
- English
- ISSNs:
- 1478-7210
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002981
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 20779.xml